1. Approvals of cancer drugs set record in 2012

    Interviewee/Contributer: Bruno Pagliara

    Organisation: On-kòs Pharma Consulting

    Read more

  2. Do oncolytic viruses have a future as combination therapies?

    Interviewee/Contributer: Steven Powell

    Organisation: Virttu Biologics Ltd

    Read more

  3. Diabetes reimbursement at risk in Germany

    Interviewee/Contributer: Karen Finn

    Organisation: MedNous

    Read more

  4. Unitary patent - for better or for worse?

    Interviewee/Contributer: Will James

    Organisation: Marks and Clerk Solicitors LLP

    Read more

  5. 2012 was the year of the antibody developer

    Interviewee/Contributer: William Ellington

    Organisation: MedNous

    Read more

  6. Sofinnova's Investment Strategy: Putting the entrepreneur first

    Interviewee/Contributer: Antoine Papiernik

    Organisation: Sofinnova Partners

    Read more

  7. Are botanical drugs a new model for pharma?

    Interviewee/Contributer: Christian Hogg

    Organisation: Hutchison China MediTech

    Read more

  8. Managers ignore pharmacovigilance at their peril

    Interviewee/Contributer: Johan Strömquist

    Organisation: NDA Group

    Read more

  9. Adaptive licensing: A new approach for drug approvals

    Interviewee/Contributer: Karen Finn

    Organisation: MedNous

    Read more

  10. IMI: As Big Pharma pulls back, IMI steps in

    Interviewee/Contributer: Michel Goldman

    Organisation: Innovative Medicines Initiative

    Read more